These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 17475450)

  • 21. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections.
    Stein GE; Schooley S; Peloquin CA; Missavage A; Havlichek DH
    J Antimicrob Chemother; 2007 Oct; 60(4):819-23. PubMed ID: 17673476
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimicrobial susceptibility patterns of some recently established coryneform bacteria.
    Funke G; Pünter V; von Graevenitz A
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2874-8. PubMed ID: 9124857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii.
    Guna R; Muñoz C; Domínguez V; García-García A; Gálvez J; de Julián-Ortiz JV; Borrás R
    J Antimicrob Chemother; 2005 Jun; 55(6):950-3. PubMed ID: 15824090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kinetics and quantification of antibacterial effects of beta-lactams, macrolides, and quinolones against gram-positive and gram-negative RTI pathogens.
    Schaper KJ; Schubert S; Dalhoff A
    Infection; 2005 Dec; 33 Suppl 2():3-14. PubMed ID: 16518706
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of ciprofloxacin, moxifloxacin, vancomycin and erythromycin against planktonic and biofilm forms of Corynebacterium urealyticum.
    Soriano F; Huelves L; Naves P; Rodríguez-Cerrato V; del Prado G; Ruiz V; Ponte C
    J Antimicrob Chemother; 2009 Feb; 63(2):353-6. PubMed ID: 19056748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Wound infections due to opportunistic corynebacterium species].
    Olender A; Łetowska I
    Med Dosw Mikrobiol; 2010; 62(2):135-40. PubMed ID: 20873486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of DX-619 compared to other agents against viridans group streptococci, Streptococcus bovis, and Cardiobacterium hominis.
    Kosowska-Shick K; Smith K; Bogdanovich T; Ednie LM; Jones RN; Appelbaum PC
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4191-4. PubMed ID: 17043120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro susceptibility of Bacillus anthracis to various antibacterial agents and their time-kill activity.
    Athamna A; Massalha M; Athamna M; Nura A; Medlej B; Ofek I; Bast D; Rubinstein E
    J Antimicrob Chemother; 2004 Feb; 53(2):247-51. PubMed ID: 14688054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Usefulness of various antibiotics against Mycobacterium avium-intracellulare, measured by their mutant prevention concentration.
    Rodríguez JC; Cebrián L; López M; Ruiz M; Royo G
    Int J Antimicrob Agents; 2005 Mar; 25(3):221-5. PubMed ID: 15737516
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis.
    Rodríguez JC; Cebrián L; López M; Ruiz M; Jiménez I; Royo G
    J Antimicrob Chemother; 2004 Mar; 53(3):441-4. PubMed ID: 14963069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In-vitro activity of levofloxacin, ofloxacin and D-ofloxacin against coryneform bacteria and Listeria monocytogenes.
    Martínez-Martínez L; Pascual A; Suárez AI; Perea EJ
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():27-32. PubMed ID: 10404334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New agents in development for the treatment of bacterial infections.
    Abbanat D; Morrow B; Bush K
    Curr Opin Pharmacol; 2008 Oct; 8(5):582-92. PubMed ID: 18761107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia.
    Morrissey I; Ge Y; Janes R
    Int J Antimicrob Agents; 2009 Jun; 33(6):515-9. PubMed ID: 19203863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro susceptibilities of aerobic and facultative non-spore-forming gram-positive bacilli to HMR 3647 (RU 66647) and 14 other antimicrobials.
    Soriano F; Fernández-Roblas R; Calvo R; García-Calvo G
    Antimicrob Agents Chemother; 1998 May; 42(5):1028-33. PubMed ID: 9593121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp.
    Drago L; Nicola L; De Vecchi E
    Clin Microbiol Infect; 2008 Jun; 14(6):608-11. PubMed ID: 18397336
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activities of ketolide HMR 3647, macrolides, and clindamycin against Coryneform bacteria.
    Martínez-Martínez L; Pascual A; Suárez AI; Perea EJ
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3290-2. PubMed ID: 9835530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective study of catalase-positive coryneform organisms in clinical specimens: identification, clinical relevance, and antibiotic susceptibility.
    Lagrou K; Verhaegen J; Janssens M; Wauters G; Verbist L
    Diagn Microbiol Infect Dis; 1998 Jan; 30(1):7-15. PubMed ID: 9488824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
    Steinkraus G; White R; Friedrich L
    J Antimicrob Chemother; 2007 Oct; 60(4):788-94. PubMed ID: 17623693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natural antibiotic susceptibility of recently established coryneform bacteria.
    Troxler R; Funke G; Von Graevenitz A; Stock I
    Eur J Clin Microbiol Infect Dis; 2001 May; 20(5):315-23. PubMed ID: 11453591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of linezolid against clinical isolates of Fusobacterium spp.
    Daeschlein G; Hoehne C; Assadian O; Daxboeck F; Meinl C; Kramer A; Kekulé AS
    J Antimicrob Chemother; 2006 Oct; 58(4):789-93. PubMed ID: 16905529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.